cancer pain

hydrocotarnine is an inhibitor of Cbl.

Pranoprofen (Pyranoprofen) (INN) is a non-steroidal anti-inflammatory drug used in ophthalmology.

Zoledronic Acid (ZOL 446) is a bisphosphonate. Zoledronic Acid (ZOL 446) is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases. An annual dose of Zoledronate may also prevent recurring fractures in patients with a previous hip fracture. Zoledronic Acid (ZOL 446) is a single 5 mg infusion for the treatment of Paget's disease of bone. In 2007, the FDA also approved Reclast for the treatment of postmenopausal osteoporosis.

S-Adenosyl-L-methionine disulfate tosylate is a methyl donor with oral activity. S-Adenosyl-L-methionine disulfate tosylate is a dietary supplement with effective antidepressant and pain-relieving effects. S-Adenosyl-L-methionine disulfate tosylate also has anti-proliferative, pro-apoptotic and anti-metastatic effects in cancer. S-Adenosyl-L-methionine can be used in the research of liver diseases and osteoarthritis.

Neurotensin TFA (39379-15-2 free base) is an endogenous 13 amino acid neuropeptide with profound opioid-independent analgesic effects. It behaves as a neurotransmitter in the brain, as a hormone in the gut, and also as a neuromodulator. It is implicated in the pathophysiology of several CNS disorders (including schizophrenia, Parkinson's disease, drug abuse, pain, cancer, inflammation, eating disorders, and central control of blood pressure) due to its association with a wide variety of neurotransmitter systems such as dopaminergic, sertonergic, glutamatergic, GABAergic, and cholinergic systems. It has a role as a human metabolite, a mitogen, a neurotransmitter and a vulnerary.

Ketorolac (RS37619) hydrochloride is a nonsteroidal anti-inflammatory drug and a non-selective COX inhibitor, exhibiting IC50 values of 20 nM for COX-1 and 120 nM for COX-2. This compound is utilized in a 0.5% ophthalmic solution format for the investigation of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and post-operative ocular inflammation pain. Additionally, Ketorolac hydrochloride serves as a DDX3 inhibitor, making it pertinent for research in cancer therapies.

DWP-05195 is a TRPV1 antagonist capable of inhibiting pain signal transduction. Additionally, it induces ER stress-dependent apoptosis in human ovarian cancer cells via the ROS-p38-CHOP pathway.

DBPR116 is a prodrug of BPRMU191 that can penetrate the blood-brain barrier. It significantly enhances the delivery efficiency of drugs targeting the central nervous system. When combined with the antagonist Naltrexone, DBPR116 demonstrates superior safety and analgesic effects compared to morphine in various in vivo pharmacological studies, including thermal pain models, cancer pain models, constipation, sedation, psychological dependence, heart rate, and respiratory frequency. As a strategy for peripheral administration, DBPR116 effectively alleviates pain while reducing adverse effects, showing promise as a safer opioid analgesic.

P2X4 antagonist-3 (Compound 14c) is a P2X4 inhibitor with an IC50 value of 1.2 μM. It holds potential for research into neuroinflammation, chronic pain, and cancer progression.

PIP5K1C-IN-1 (Compound 30) is a potent PIP5K1C inhibitor with an IC50 of 0.80 nM. In mice, it exhibits low total clearance and high kinase selectivity, making it useful for research in cancer and chronic pain.

MDA-19 N-(5-hydroxyhexyl) is a cannabinoid receptor modulator that targets CB1R/CB2R. It is applicable in research related to neurological disorders, cancer, and pain regulation.

MAGL-IN-22 (Compound 40) is a reversible, competitive, and selective inhibitor of MAGL that is capable of crossing the blood-brain barrier, with an IC50 of 0.34 μM for hMAGL. It exhibits significant antioxidant and anti-inflammatory properties, activating the Nrf2 pathway and markedly suppressing NFκB-mediated inflammation, without inducing cytotoxic effects. MAGL-IN-22 is applicable in research on neurodegenerative diseases, chronic pain, and cancer.

(R)-Amlodipine is the R-enantiomer of Amlodipine and functions as an orally active dihydropyridine calcium channel blocker with antianginal properties, (R)-Amlodipine excerts its effect by blocking voltage-dependent L-type calcium channels and thus reducing calcium influx into cells. (R)-Amlodipine can be employed in research concerning high blood pressure and cancer, as (R)-Amlodipine calcium channel regulation ability provide a mechanistic basis for investigating cardiovascular disorders and tumor-related pathophysiology.

HA 155 (Autotaxin Inhibitor IV) is a boronic acid-based compound, inhibiting ATX with IC50 of 5.7 nM by selectively binding to its catalytic threonine.

EP4 receptor antagonist 3 is a highly potent and specific inhibitor of the EP4 receptor, intended for research purposes in studying EP4 receptor-mediated diseases, including acute and chronic pain, osteoarthritis, rheumatoid arthritis, and cancer.

1. Obtusifolin has antioxidant properties and improves chemically induced diabetes and its complications by modulation of oxidative stress. 2. Obtusifolin suppresses phthalate esters-mediated bone resorption, thus may be a novel anti-breast-cancer bone me

3-(3,6-dichloro-9H-carbazol-9-yl)propanoic acid (DCPPA) is an ASIC3 inhibitor that effectively blocks ASIC3-mediated pain and inflammation. It has been shown to have potential applications in the treatment of other diseases such as stroke, epilepsy and cancer.

1. Koumine can treat the diabetic neuropathy. 2. Koumine has antineoplastic effect, may be a future breast cancer chemotherapeutic agent. 3. Koumine has a significant analgesic effect in rodent behavioral models of inflammatory and neuropathic pain, the m

Ketorolac (RS37619) hemicalcium is a nonselective COX inhibitor with IC50 values of 20 nM for COX-1 and 120 nM for COX-2. This non-steroidal anti-inflammatory drug (NSAID) is used as a 0.5% ophthalmic solution for researching allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Additionally, it is a DDX3 inhibitor applicable in cancer research [1] [4].

Sulindac (sodium) (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac (sodium) is used to reduce pain, swelling, and joint stiffness from arthritis. Sulindac is also used for the research of arthritis of the spine, gouty arthritis. Sulindac (sodium), as an immunomodulatory agent, can downregulate PD-L1 through the blockade of NF-κB signaling and modulates the response of pMMR colorectal cancer (CRC) to anti-PD-L1 immunotherapy, inhibits the development and progression of colorectal cancer CRC. Sulindac (sodium) also inhibits TGF-β1- induced epithelial-mesenchymal transition (EMT) and suppresses lung cancer cell migration and invasion via downregulation of SIRT1 [1] [2].

COX-2-IN-18 is a potent and selective COX-2 inhibitor (IC50 = 30 nM). It alleviates inflammation and pain by inhibiting PGE2 production in autoimmune research.

ATX inhibitor 10 is a nitrogen-containing heterocyclic compound that is a potent inhibitor of ATX. Among other things, ATX plays a role in causing pathologies including fibrosis, neurodegeneration, arthritis, neuropathic pain, and cancer. ATX inhibitor 10 has shown research potential for ATX-related diseases.

RORγt modulator 3 is a modulator of retinol-related orphan receptor γt (RORγt) and can be used to study RORγt-mediated diseases such as pain, COPD, inflammation, asthma, colitis, multiple sclerosis, rheumatoid arthritis, psoriasis, neurodegenerative diseases and cancer.

(3S,4R)-PF-6683324 is a pro-myosin-related kinase (Trk) inhibitor with research potential for pain and cancer.